

## DAFTAR PUSTAKA

- Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J. W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., Benedetti, A., Bisson, G. P., Boeree, M. J., Bonnet, M., Brode, S. K., Brust, J. C. M., Cai, Y., Caumes, E., Cegielski, J. P., ... Menzies, D. (2018). Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. *The Lancet*, *392*(10150), 821–834. [https://doi.org/10.1016/S0140-6736\(18\)31644-1](https://doi.org/10.1016/S0140-6736(18)31644-1)
- Ajay Handa, Sahajal Dhooria, Inderpaul Singh Sehgal, & Ritesh Agarwal. (2018). Primary cavitary sarcoidosis: A case report, systematic review, and proposal of new diagnostic criteria. *Lung India*, *35*(1), 41–46. <https://doi.org/10.4103/lungindia.lungindia>
- Aromataris, 2015, Checklist\_for\_Systematic\_Reviews\_and\_Research\_Syntheses.* (n.d.).
- Bastos, M. L., Lan, Z., & Menzies, D. (2017). An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. *European Respiratory Journal*, *49*(3). <https://doi.org/10.1183/13993003.00803-2016>
- Chris, D. M. Z. L. N. A. P. B. L. B. A. B. S. K. B. J. C. M. B. J. R. C. V. W. L. C. D. F. L. G. P. I. R. R. K. M. K. L. (2020). Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: *Physiology & Behavior*, *8*(4), 383–394. [https://doi.org/10.1016/S2213-2600\(20\)30047-3](https://doi.org/10.1016/S2213-2600(20)30047-3). Drug-associated
- Ding, P., Li, X., Jia, Z., & Lu, Z. (2017). Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: A systematic review and spatio-temporal analysis. *BMC Infectious Diseases*, *17*(1), 1–29. <https://doi.org/10.1186/s12879-016-2151-5>
- Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: Definitions, diagnosis, and management. *Lancet*, *356*(9237), 1255–1259. [https://doi.org/10.1016/S0140-6736\(00\)02799-9](https://doi.org/10.1016/S0140-6736(00)02799-9)
- Endo, Y., Jaramillo, J., Research, R. Y.-T., & 2022, undefined. (2022). Patient and Health-System-Related Barriers to Treatment Adherence for Patients with Drug-Resistant Tuberculosis in the Philippines: A Mixed-Methods Study. *Downloads.Hindawi.Com*. <https://doi.org/10.1155/2022/6466960>
- FDA. (2021). Treatment of Tuberculosis Disease. *Nature Genetics*, *45*(10), 1183–1189.
- GB, P. (2011). Faktor-faktor yang Mempengaruhi Terjadinya Resistensi Rifampicin dan Isoniazid pada Pasien Tuberkulosis Paru di BKPM Semarang. *Artikel Karya Tulis Ilmiah*, 1–24.
- Gupta, A., Kumar, V., Natarajan, S., & Singla, R. (2020). Adverse drug reactions & drug interactions in MDR-TB patients. *Indian Journal of Tuberculosis*, *67*(4), S69–S78. <https://doi.org/10.1016/j.ijtb.2020.09.027>

- Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (2019). Cochrane handbook for systematic reviews of interventions. *Cochrane Handbook for Systematic Reviews of Interventions*, October, 1–694. <https://doi.org/10.1002/9781119536604>
- Hong, H. (2020). *Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose*. 2(1), 1–17. <https://doi.org/10.5588/ijtld.19.0062.Risk>
- Huerga, H., Khan, U., Bastard, M., Mitnick, C. D., Lachenal, N., Khan, P. Y., Seung, K. J., Melikyan, N., Ahmed, S., Rich, M. L., Varaine, F., Osso, E., Rashitov, M., Salahuddin, N., Salia, G., Sánchez, E., Serobyian, A., Rafi Siddiqui, M., Grium Tefera, D., ... Hewison, C. (2022). Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. *Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America*, 75(8), 1307–1314. <https://doi.org/10.1093/cid/ciac176>
- Jang, J. G., & Chung, J. H. (2020). *Diagnosis and treatment of multidrug-resistant tuberculosis*. 37(4), 277–285.
- Kemendes. (2020). *Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat Di Indonesia*.
- Kementrian Kesehatan Republik Indonesia. (2014). *Pedoman Nasional Pengendalian Tuberkulosis*.
- Krasniqi, S., Neziri, B., Jakupi, A., Shurdhaj, I., Daci, A., Jupolli-Krasniqi, N., & Pira, M. (2020). Tuberculosis drug safety and pharmacovigilance in health system of Kosova: A cross-sectional analysis. *Pharmacoepidemiology and Drug Safety*, 29(9), 1037–1045. <https://doi.org/10.1002/pds.5076>
- Lan, Z., Ahmad, N., Baghaei, P., Barkane, L., Benedetti, A., & Al., E. (2020). Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. *The Lancet. Respiratory Medicine*, 8(4), 383–394. [https://doi.org/10.1016/S2213-2600\(20\)30047-3](https://doi.org/10.1016/S2213-2600(20)30047-3)
- Murti Bhisma. (2018). *Teori Kesehatan dan Promosi*.
- Mustafa, T., Shahzad, Y., & Kiani, A. (2018). A survey of knowledge, attitude, and practices of private retail pharmacies staff in tuberculosis care: Study from Dera Ismail Khan City, Pakistan. *Journal of Pharmaceutical Policy and Practice*, 11(1), 1–7. <https://doi.org/10.1186/s40545-018-0134-1>
- Nurismi. (1967). *FAKTOR - FAKTOR YANG BERHUBUNGAN DENGAN TERJADINYA MULTI DRUG RESISTENT PADA PASIEN TUBERKULOSIS PARU TERHADAP PENYEMBUHAN DI POLIKLINIK TB-MDR RSUD. LABUANG BAJI MAKASSAR*. 3, 5–24. <https://medium.com/@arifwicaksanaa/pengertian-use-case-a7e576e1b6bf>

- O'Donnell, J. (1994). Adverse drug reactions. *Legal Medicine*, 229–267. [https://doi.org/10.5005/jp/books/12112\\_29](https://doi.org/10.5005/jp/books/12112_29)
- Oh, A., Makmor-Bakry, M., Islahudin, F., Health, I. W.-B. global, & 2023, U. (2022). Prevalence and predictive factors of tuberculosis treatment interruption in the Asia region: a systematic review and meta-analysis. *Gh.Bmj.Com*. <https://gh.bmj.com/content/8/1/e010592.abstract>
- Organization, W. H. (2020). *Comprehensive TB guidelines for national tuberculosis program*. <https://apps.who.int/iris/bitstream/handle/10665/333647/TLS-NTP-manual-eng.pdf>
- Patton, K., & Borshoff, D. C. (2018). Adverse drug reactions. *Anaesthesia*, 73, 76–84. <https://doi.org/10.1111/anae.14143>
- Pujiyani, H. (2019). Faktor Risiko Kejadian Preeklampsia. *Jurnal Ilmu Kesehatan Immanuel*, 12(2), 30–36. <https://doi.org/10.36051/jiki.v12i2.65>
- Resende, L. S. O., & Santos-Neto, E. T. dos. (2015). Fatores de risco associados às reações adversas a medicamentos antituberculose. *Jornal Brasileiro de Pneumologia*, 41(1), 77–89. <https://doi.org/10.1590/S1806-37132015000100010>
- Reviono, Kusnanto, P., Eko, V., Pakiding, H., & Nurwidiasih, D. (2014). Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberculosis. *Majalah Kedokteran Bandung*, 46(4), 189–196. <https://doi.org/10.15395/mkb.v46n4.336>
- Schnippel, K., Firnhaber, C., Berhanu, R., Page-Shipp, L., & Sinanovic, E. (2017). Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: A systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy*, 72(7), 1871–1879. <https://doi.org/10.1093/jac/dkx107>
- Siswanto. (2010). Systematic Review Sebagai Metode Penelitian Untuk Mensintesis Hasil-Hasil Penelitian (Sebuah Pengantar) (Systematic Review as a Research Method to Synthesize Research Results (An Introduction)). *Buletin Penelitian Sistem Kesehatan*, 13(4), 326–333.
- Skrahina, A., Hurevich, H., Zalutskaya, A., Sahalchyk, E., Astrauko, A., Hoffner, S., Rusovich, V., Dadu, A., de Colombani, P., Dara, M., van Gemert, W., & Zignol, M. (2013). Tuberculosis multiresistente en Bielorrusia: Magnitud del problema y factores de riesgo asociados. *Bulletin of the World Health Organization*, 91(1), 36–45. <https://doi.org/10.2471/BLT.12.104588>
- Traore, B., Tsoumbou Bakana, G., Nani, S., & Hassoune, S. (2021). Risk Management Assessments of Anti-tuberculosis Adverse Drug Reaction: A Systematic Review. *E3S Web of Conferences*, 319. <https://doi.org/10.1051/e3sconf/202131901042>
- Tuberculosis*. (2020). <https://doi.org/10.1787/f494a701-en>

- WHO. (2022). WHO: operational handbook on tuberculosis. In *Module 5: Management of tuberculosis in children and adolescents*. <https://apps.who.int/iris/bitstream/handle/10665/340256/9789240022614-eng.pdf>
- Wokas, J. A. J., Wongkar, M. C. P., & Surachmanto, E. (2015). Hubungan Antara Status Gizi, Sputum Bta Dengan Gambaran Rontgen Paru Pada Pasien Tuberkulosis. *E-CliniC*, 3(1). <https://doi.org/10.35790/ecl.3.1.2015.6833>
- World Health Organization. (2020). Are Updated Every Year . for the Tuberculosis. In *Global Tuberculosis Report*.
- Zhang, C., Wang, Y., Shi, G., Han, W., Zhao, H., Zhang, H., & Xi, X. (2016). Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study. *BMC Public Health*, 16(1), 1–8. <https://doi.org/10.1186/s12889-016-2711-z>
- Zhao, P., Li, X. J., Zhang, S. F., Wang, X. S., & Liu, C. Y. (2012). Social behaviour risk factors for drug resistant tuberculosis in mainland china: A meta-analysis. *Journal of International Medical Research*, 40(2), 436–445. <https://doi.org/10.1177/147323001204000205>